Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Finranks

Kompaniya

  • Biz haqimizda

Biz bilan bog'lanish

  • [email protected]

Bizni kuzating

  • Instagram
  • Telegram
  • LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari
  • Bosh sahifa
  • Bozorlar
  • Skriner
  • Yangiliklar
  • Biz haqimizda
  1. Home
  3. MLYS
M

Mineralys Therapeutics, Inc. (MLYS)

NMS – Real vaqt narxi. Valyuta: USD

23.68

+0.07 (0.30%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

23.68

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:34 PM EDT

  • Umumiy
  • Yangiliklar
  • Grafik
  • Hisobotlar
  • Dividendlar
  • Kutilma
  • Egalik
  • Profil

Videolar

No Data

There is no data to display

Press-relizlar

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
24.03.2026

Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer

RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced the appointment of Jeffrey A.

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
12.03.2026

Mineralys Therapeutics Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update

–  Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 – – Conference call today at 4:30 p.m. ET – RADNOR, Pa.

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results
09.03.2026

Mineralys Therapeutics Announces FDA Acceptance of NDA for Lorundrostat for Treatment of Adults with Hypertension and Topline Explore-OSA Trial Results

– The FDA assigned a PDUFA target action date of December 22, 2026 – – The NDA is based on positive data from a successful clinical program demonstrating favorable safety and blood pressure reduction in adults with hypertension – – Topline results from the Phase 2 Explore-OSA exploratory trial did not reduce AHI; demonstrated a clinically meaningful reduction in blood pressure and favorable safety and tolerability in this population with difficult to control hypertension – RADNOR, Pa., March 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for lorundrostat for the treatment of adult patients with hypertension in combination with other antihypertensive drugs.

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
26.02.2026

Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, announced today that on February 23, 2026, the Compensation Committee of Mineralys' Board of Directors granted an inducement stock option award covering 27,920 shares and an inducement restricted stock unit award covering 20,940 shares of Mineralys common stock to one new non-executive employee.